Key Takeaways:
Lunai Bioworks, Inc. (Nasdaq: LNAI) filed a federal lawsuit on May 11 against unidentified "naked" short sellers, alleging a stock manipulation scheme that saw trading volumes reach over 15 times the company's total outstanding shares.
"The abusive, fraudulent and manipulative practice of ‘naked’ short selling causes real market harm, particularly to dynamic micro and mid-cap entrepreneurial public companies," Jacob Frenkel, Securities Enforcement Practice Chair at Dickinson Wright and co-lead counsel for Lunai, said.
The complaint, filed in the District of Delaware, details multiple instances of extreme trading activity. On March 17, 2026, trading volume hit 554,032,865 shares, or 15.3 times Lunai’s approximately 36 million outstanding shares. The suit also notes that failures-to-deliver shares reached as high as 234.6 times the baseline rate, at one point representing 81.6% of all outstanding shares.
This legal action follows a period of significant business achievements for the AI-driven precision medicine company, including positive preclinical data for a cancer immunotherapy. Despite these developments, the complaint notes the company's stock price fell 20.6% from $1.17 to $0.93 in just two days following a major breakthrough announcement. The lawsuit alleges this price drop was a direct result of the illegal shorting activity.
The lawsuit was brought by law firms Dickinson Wright and Fox Rothschild, who are representing Lunai. The complaint asserts three counts: securities fraud, market manipulation, and the intentional tort of wire fraud. It alleges a "coordinated and systematic scheme" by the "John Doe" defendants to depress Lunai's stock price through illegal "naked" short selling, where sellers don't borrow or arrange to borrow the shares before selling them.
"The data tell a stark story – coordinated volume spikes, synchronized failure to deliver clusters, and exploitation of regulatory thresholds that are inconsistent with legitimate market activity," Sidney Liebesman, Senior Litigation Partner at Fox Rothschild and co-lead counsel, said.
The suit highlights that on multiple days, the number of shares traded was several times the approximately 26 million shares that were actually available to be traded. The law firms have stated their intent to pursue expedited discovery to identify the defendants and seek emergency injunctive relief to halt the trading.
The legal action by Lunai Bioworks could set a precedent for other small-cap companies facing similar manipulation concerns. A successful outcome for Lunai may not only result in significant compensatory damages but also force the covering of illicit short positions, potentially affecting the stock's market dynamics. Investors will be watching for the identification of the "John Doe" defendants as the case proceeds.
This article is for informational purposes only and does not constitute investment advice.
